Insulin Glargine and NPH Insulin Increase to a Similar Degree Epithelial Cell Proliferation and Aberrant Crypt Foci Formation in Colons of Diabetic Mice

Hormones and Cancer

Volumn 1, Issue 6, 2010, Pages 320-330

  Nagel, Jutta M ^a,b   Staffa, Jürgen ^a   Renner Müller, Ingrid ^c   Horst, David ^d   Vogeser, Michael ^a   Langkamp, Markus ^e   Hoeflich, Andreas ^f   Göke, Burkhard ^a   Kolligs, Frank T ^a   Mantzoros, Christos S ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MUNICH   (Germany)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e Mediagnost GmbH   (Germany)

^f LEIBNIZ INSTITUTE FOR FARM ANIMAL BIOLOGY FBN   (Germany)

Author keywords

Aberrant crypt foci; Glargine; NPH insulin; Proliferation; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSUMAN BASAL; ISOPHANE INSULIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CANCER STAGING; CELL PROLIFERATION; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; CRYPT CELL; DIABETES MELLITUS; DRUG EFFECT; EPITHELIUM CELL; FEMALE; FOOD INTAKE; INSULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; CELL PROLIFERATION; COLON; DIABETES MELLITUS, TYPE 2; EPITHELIAL CELLS; FEMALE; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MICE;

EID: 78650190900     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-010-0020-z     Document Type: Article

References (42)

1. Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97: 1679-1687.
2. Berster JM, Goke B (2008) Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem 114: 84-98.
3. Manousos O, Souglakos J, Bosetti C et al (1999) IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 83: 15-17.
4. Keown-Eyssen G (1994) Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 3: 687-695.
5. Giovannucci E (1995) Insulin and colon cancer. Cancer Causes Control 6: 164-179.
6. Li G, Barrett EJ, Wang H et al (2005) Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. Endocrinology 146: 4690-4696.
7. Strasser-Vogel B, Blum WF, Past R et al (1995) Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment. J Clin Endocrinol Metab 80: 1207-1213.
8. Michell NP, Dent S, Langman MJ et al (1997) Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell proliferation. Growth Factors 14: 269-277.
9. Baserga R (1995) The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55: 249-252.
10. Yang YX, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127: 1044-1050.
11. Bowker SL, Majumdar SR, Veugelers P et al (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258.
12. Tran TT, Naigamwalla D, Oprescu AI et al (2006) Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology 147: 1830-1837.
13. Hirose Y, Hata K, Kuno T et al (2004) Enhancement of development of azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice. Carcinogenesis 25: 821-825.
14. Roncucci L, Pedroni M, Vaccina F et al (2000) Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Prolif 33: 1-18.
15. Gerich JE (2004) Insulin glargine: long-acting basal insulin analog for improved metabolic control. Curr Med Res Opin 20: 31-37.
16. Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49: 999-1005.
17. Stammberger I, Bube A, Durchfeld-Meyer B et al (2002) Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 21: 171-179.
18. Colhoun HM (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52: 1755-1765.
19. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777.
20. Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 53: 1732-1744.
21. Jonasson JM, Ljung R, Talback M et al (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52: 1745-1754.
22. Hummel KP, Dickie MM, Coleman DL (1966) Diabetes, a new mutation in the mouse. Science 153: 1127-1128.
23. Steeb CB, Trahair JF, Tomas FM et al (1994) Prolonged administration of IGF peptides enhances growth of gastrointestinal tissues in normal rats. Am J Physiol 266: G1090-G1098.
24. Steeb CB, Trahair JF, Read LC (1995) Administration of insulin-like growth factor-I (IGF-I) peptides for three days stimulates proliferation of the small intestinal epithelium in rats. Gut 37: 630-638.
25. Deindl E, Zaruba MM, Brunner S et al (2006) G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J 20: 956-958.
26. Diehl D, Oesterle D, Elmlinger MW et al (2006) IGF-II transgenic mice display increased aberrant colon crypt multiplicity and tumor volume after 1, 2-dimethylhydrazine treatment. J Carcinog 5: 24.
27. Wolf E, Kramer R, Blum WF et al (1994) Consequences of postnatally elevated insulin-like growth factor-II in transgenic mice: endocrine changes and effects on body and organ growth. Endocrinology 135: 1877-1886.
28. Ju JH, Nolan B, Cheh M et al (2008) Voluntary exercise inhibits intestinal tumorigenesis in Apc(Min/+) mice and azoxymethane/dextran sulfate sodium-treated mice. Bmc Cancer 8: 316.
29. Brunt EM, Janney CG, Di Bisceglie AM et al (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467-2474.
30. Wu Y, Yakar S, Zhao L et al (2002) Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62: 1030-1035.
31. Koohestani N, Tran TT, Lee W et al (1997) Insulin resistance and promotion of aberrant crypt foci in the colons of rats on a high-fat diet. Nutr Cancer 29: 69-76.
32. Tran TT, Gupta N, Goh T et al (2003) Direct measure of insulin sensitivity with the hyperinsulinemic-euglycemic clamp and surrogate measures of insulin sensitivity with the oral glucose tolerance test: correlations with aberrant crypt foci promotion in rats. Cancer Epidemiol Biomarkers Prev 12: 47-56.
33. Weinstein D, Simon M, Yehezkel E et al (2009) Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25: 41-49.
34. Shukla A, Grisouard J, Ehemann V et al (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16: 429-441.
35. Kuerzel GU, Shukla U, Scholtz HE et al (2003) Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 19: 34-40.
36. Agin A, Jeandidier N, Gasser F et al (2007) Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab 33: 205-212.
37. Slawik M, Schories M, Busse Grawitz A et al (2006) Treatment with insulin glargine does not suppress serum IGF-1. Diabet Med 23: 814-817.
38. Diehl D, Hessel E, Oesterle D et al (2009) IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer 124: 2220-2225.
39. Hoflich A, Lahm H, Blum W et al (1998) Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of ICF-responsive colon carcinoma cell lines. Febs Letters 434: 329-334.
40. Bermont L, Lamielle F, Fauconnet S et al (2000) Regulation of vascular endothelial growth factor expression by insulin-like growth factor-1 in endometrial adenocarcinoma cells. Int J Cancer 85: 117-123.
41. Bermont L, Lamielle F, Lorchel F et al (2001) Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells. J Clin Endocrinol Metab 86: 363-368.
42. Nagel JM, Mansmann U, Wegscheider K et al (2010) Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine. Diabetologia 53: 206-208.